Press Releases

New York, NY, May 23, 2024 (GLOBE NEWSWIRE) -- Optimum AI is set to revolutionize the Decentralized Finance (DeFi) landscape with its innovative text-based trading platform, now accessible through popular messaging apps WhatsApp and Telegram. This groundbreaking approach aims to simplify DeFi participation by allowing users to execute trades, bridge assets across blockchains, and access contract audits using simple text commands.

Optimumai tech

RANCHO CUCAMONGA, Calif., May 23, 2024 /PRNewswire/ -- Inland Empire Health Plan (IEHP) broke ground on its new Community Wellness Center (CWC) in San Bernardino on May 22, inviting health plan leaders and city officials to view the site for the first time.

The two-story, 33,000-square-foot space at 2050 N. Massachusetts Ave. will replace the existing... (continue reading...)

• Omlyclo® (CT-P39), used to treat allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic spontaneous urticaria (CSU), becomes the first omalizumab biosimilar approved in the European Union
• The European Commission (EC) decision is based on clinical evidence, including results from a Phase III clinical trial demonstrating a comparable efficacy and safety profile with the reference product Xolair®
• Omlyclo® is the first omalizumab... (continue reading...)

In the news release, IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma, issued 23-May-2024 by IDEAYA Biosciences, Inc. over PR Newswire, we are advised by the company that the percent value pertaining to "median tumor shrinkage (maximum value change)" in the subheadline and 4th paragraph, should read "approximately 45% after 6 months" rather than... (continue reading...)

SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting are now available on ASCO's official website. These abstracts report on the company's three lead drug... (continue reading...)